Weibo
WeChat
The 8th World-China  Pharmaceutical R&D Congress

You can share it to WeChat via the Qr code.

Events
The 8th World-China  Pharmaceutical R&D Congress

Enter the applet sharing event using WeChat scan.

Background

In 2015, BIOMAP founded the first Chemical drug R&D Forum. After eight sessions , it has been working with Chinese  small molecule pharmaceutical enterprises all the way, witnessing the historical process from generic drugs to innovative drugs, and accompanying the development and growth of small molecule pharmaceutical industry across the region. The forum gathers KOL in Drug Discovery, Regulatory Affairs, pharmaceutical CMC and other fields to discuss and promote the development of Small Molecule Chemical Drugs across the region!

As more and more innovative pharmaceutical enterprises reach the end of the marathon and get product launched, and more and more new technologies innovate the traditional pharmaceutical pattern, pharmaceutical companies are still facing severe challenges:

· How to face the continuous questions from pre NDA meeting 

· Facing the severe challenge of homogenizationhow to differentiate the layout of the next product?

· Under the system of medical insurance and centralized procurement of drugs, how to establish the competition barriers of new drugs that really meet the clinical needs?

· How do AI/PROTACand other revolutionary technologies improve the druggability and accelerate clinical transformation?

In the spring of 2022, PharmaCon 2022 The 8th World-China Pharmaceutical R&D Congress will set sail again, focusing on " Innovative Small Molecular Drugs " with the theme of "Build Innovative Small Molecular Drugs Barriers to Competitiveness, Meet the Challenges of Druggability and NDA", moving from pseudo-innovation to source innovation.

The conference will set up two parallel sub-forums, which will invite 60+leading enterprises, research scholars, regulatory experts and scientists in the field of small molecule innovative drug R&D. PharmaCon involves 2 days of wonderful sharing and discussion centered on  class 1 small molecule innovative drugs in tumor and non-tumor fields under new technology platform (PROTAC/ AIDD/CADD/SBDD/FBDD/DEL, etc.) and changes in CMC and NDA application challenges to accelerate  differentiated project initiation, drug discovery and CMC NDA process of innovative small-molecule drugs!

亮点与人群

图-05.pngHighlights

★ To catch them all! From the drug discovery to CMC to address the practical challenges of small molecule innovative drug development

★ To track leading practices in the development of innovative small molecule drugs targeting the "undruggable"

★ To analyze of cutting-edge innovation platform technologiesand hot categories: innovative drugs under PROTAC/ molecular glue and more TPD, AIDD/CADD/SBDD/FBDD/DEL and more……

★ To listen to the latest advances in the areas of oncology, IO, and non-tumor (Anti-Infectives, CNS)

★ To learn CMC coping strategies for clinical and post-marketing change and examination

★ To master the notes of NDA application for innovative drugs in the last mile sprint and CMC development strategy that begins with the end in mind

Structure

图-06.png

Previous Distinguished Speakers
  • Academician of CAS, Professor, Shanghai Institute of Materia Medica, CAS
    陈凯先,中国科学院院士,中国科学院上海药物研究所研究员、博士生导师,上海中医药大学教授、学术委员会主任。 现任《重大新药创制》国家重大科技专项技术副总师,中国药典委员会副主任委员,中国药学会监事长,中华中医药学会副会长。曾任上海巿科协主席、中科院上海药物所所长、上海中医药大学校长、中国中西医结合学会会长、中国药学会副理事长。
  • Former Director of Chemical Drugs Department, CDE
  • Director of Chemical Drug Control Institute, NIFDC
  • Chair, EU EMA Working Group on Pharmacokinetics PKWP
  • Director of Shanghai Institute for Food and Drug Control
    上海市食品药品检验所所长,主任药师。中华人民共和国第九届、第十届药典委员会化学药专业委员、第十一届药典委员会包材与辅料专业委员会副主任委员;中华人民共和国卫生部第一届食品安全国家标准审评委员会食品添加剂专业的委员;中国药学会制药工程专业委员会委员;中国药品监督管理研究会药品包材与辅料监督管理研究专业委员会委员;上海市药学会药事管理专业委员会委员;第二届上海市食品安全地方标准审评委员会检测专业副主任委员;上海交通大学外聘兼职硕士研究生导师;中国医药工业研究总院硕士研究生导师;《中国医药工业杂志》、《药物分析杂志》编委;《上海预防医学》杂志副主编。
  • Dean, School of Pharmacy, Shanghai Jiao Tong University
    上海交通大学特聘教授,博士生导师,药学院院长。2000年在中科院上海有机化学研究所博士毕业,2001-2004年分别在美国乔治敦大学医学中心和哈佛医学院进行博士后研究,2004-2006年担任哈佛医学院讲师。2006年入选中科院“百人计划”回国加盟上海药物研究所,入选上海市浦江人才计划和上海市优秀学科带头人计划,2011年获国家杰出青年科学基金,领衔的研究团队获2018年度科技部“创新人才推进计划”-“重点领域创新团队”称号,2019年获中组部国家“万人计划”领军人才。2020年加入上海交通大学药学院。张翱教授研究团队主要致力于药物化学技术创新推动的新药发现研究,尤其是聚焦基于天然产物的药物化学和化学生物学研究、难靶蛋白的药物设计、分子靶向个性化药物研究等领域。已发表J Am Chem Soc, Angew Chem Int Ed, Chem Sci, J Med Chem,Chem Rev, Pharmacol & Ther等SCI论文170余篇,申请国内国际专利60余项。主持研发的2个1类新药已经进入临床I期研究,多个候选新药正在进行临床前研究。
  • SVP and President of Global Research and Development, Jiangsu Hengrui
    德国Tubingen大学获有机化学博士,后赴美国Vanderbilt大学从事博士后研究。加入恒瑞前,张连山博士先后在美国礼来等国际知名药企担任要职。自1988年至今,他从事多肽方法学和新药研发工作三十余年,在抗糖尿病药物方面极有造诣;目前已发表学术文章60余篇,申请专利130余篇。加入恒瑞后,他带领团队研发了一系列具有国际竞争力的创新药,其中6个1类创新药品种已获批上市,200多项临床研究正在国内外开展。
  • Senior Professor, West China Hospital of Sichuan University, Founder& Chairman of Hangzhou Generosbio
    Famous international experts, professors and entrepreneurs in molecular biology, biochemistry and medicine. Fu Xinyuan's most important achievement in science is to discover JAK-STAT signal transduction pathway and clarify JAK-STAT in life and disease. It plays an important role. Discovered by JAK-STAT in 1993, it was ranked as the top ten major sciences by the American Journal of Science. That's one of them. Over the past 27 years, more than 40,000 papers have been published on JAK-STAT pathway. Lu, the FDA approved five drugs. In just 2018, drug sales related to this pathway amounted to $8 billion. Globally Mend his ways to save him. Fu Xinyuan Singapore Laboratory (2008-2018) originally found a new mechanism of immune inflammation: new Th-GM, T Helpers have The pathogenesis and treatment of inflammation diseases are related. It also reveals JAK-STAT signaling pathways in cancer, cardiovascular, and neurodegeneration. The mechanism of aging and regeneration. Based on original scientific discoveries, Fu Xinyuan founded GenEros BioPharma Ltd., a biopharmaceutical company registered with J. E. S. Biopharmaceuticals. Cayman Islands (2015), R&D headquarters in Hangzhou (2018 - now). Shanghai, Chengdu, Delaware, USA USA has subsidiaries. GenEros BioPharma Ltd., a leading innovative drug based on new mechanisms of inflammation, has been developed by JEAS Biopharmaceuticals. At the end of 2018, the US FDA declared that it would enter the US clinical trial soon. China's cFDA declaration is also under way. This is based on the new Mechanisms of innovative drugs will complement and even gradually replace anti-TNF-related anti-inflammatory drugs.
  • Site Head at Roche Innovation Center Shanghai
  • VP, Dean of Research Institute of New Drugs, KINTOR PHARM
  • Co-founder, Former GM& COO, Ascentage Pharma Group International
  • SVP of CMC, Jacobio Pharma
  • R&D COO, Zai Lab Limited
    阎水忠博士于1995年毕业于中国协和医科大学获博士学位后,赴美在美国芝加哥大学癌症研究所完成博士后研究。加入再鼎之前,曾就职于世界500强跨国医药集团辉瑞公司和美国科文斯公司,领导并参与多个新药研发项目以及上市的申请。2009年应邀回国加入和黄医药出任药物安全性评价和项目管理负责人。 阎博士拥有超过20年的创新药物研发和运营经验,获得了与包括美国FDA、EMA和中国药品监督管理局等全球监管机构合作的丰富经验。阎博士目前是中国医药创新促进会药物研发专业委员会副主任委员,中国毒理协会理事会理事、药物毒理与安全性评价专业委员会常务委员、中国药理学会药物毒理专业委员会委员、美国毒理学会认证专家。
  • SVP, Hinova Pharmaceuticals Inc
  • SVP, Hua Medicine
  • Previous Spectacularity

    图-07.png

    Tickets
    Preparation Stage
    Registration
    End of Event
    Choose ticket
    Type
    Price(¥)
    Sales End
    Quantity
    供应商单人全场通票(CRO、CMO、咨询机构、设备仪器及其他服务提供商)
    5,980
    2022-03-23 18:00
    Sold Out
    该门票为PharmaCon和BioCon-Antiboby两会联票。多人报名享更高优惠折扣,详情欢迎咨询:180 1793 9885 (同微信)。
    药企单人全场通票(医药研发/生产企业)
    3,980
    2022-03-23 18:00
    Sold Out
    该门票为PharmaCon和BioCon-Antiboby两会联票。多人报名享更高优惠折扣,详情欢迎咨询:180 1793 9885 (同微信)。
    科研单人全场通票(科研院所与政府研究机构)
    2,980
    2022-03-23 18:00
    Sold Out
    The ticket requires approval by the organizer.
    该门票为PharmaCon和BioCon-Antiboby两会联票。多人报名享更高优惠折扣,详情欢迎咨询:180 1793 9885 (同微信)。
    Price
    0
    Organizer
    Retrieve E-tickets
    Please enter the ticket recipient's email or cell phone
    Retrieve